Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.
Br J Pharmacol. 2004.
PMID: 15197110
Free PMC article.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2026 | 0 |
Search Results
2 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.
Br J Pharmacol. 2004 Jul;142(5):861-8. doi: 10.1038/sj.bjp.0705860. Epub 2004 Jun 14.
Br J Pharmacol. 2004.
PMID: 15197110
Free PMC article.
In this study, we present the molecular pharmacological profile of the novel nonredox-type 5-LO inhibitor CJ-13,610 that was evaluated in various in vitro assays. ...In analogy to ZM230487 and L-739.010, two closely related …
In this study, we present the molecular pharmacological profile of the novel nonredox-type 5-LO inhibitor …
Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
J Pharmacol Exp Ther. 2007 Dec;323(3):778-86. doi: 10.1124/jpet.107.128264. Epub 2007 Aug 31.
J Pharmacol Exp Ther. 2007.
PMID: 17766677
Additional pharmacological profiling of SC-236 and CJ-13,610 was performed in macrophages, the primary hepatic inflammatory cell type. In these cells, SC-236 inhibited prostaglandin (PG) E2 formation in a concentration-dependent manner, w …
Additional pharmacological profiling of SC-236 and CJ-13,610 was performed in macrophages, the primary he …
Cite